The company is not selling any resale shares under this prospectus and will not receive any of the proceeds from the sale or other disposition of resale shares by the selling stockholders.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NGNE:
- 3 Stocks to Buy Now, 12/2/2024, According to Corporate Insiders
- Neurogene Adjusts Clinical Trial After Setback
- Neurogene price target lowered to $45 from $60 at BMO Capital
- Neurogene Inc. Faces Uncertainty with NGN-101 Program Amid FDA Challenges and Strategic Hurdles
- Neurogene price target lowered to $46 from $72 at Baird